Patents by Inventor Dachun Liu
Dachun Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139809Abstract: An apparatus and method for preparing high-purity spherical magnesium and/or high-purity magnesium powder are provided. The apparatus includes a vertical furnace body, a heating zone, and a condensing zone, where a periphery of the condensing zone is provided with a first thermal insulation device and a second thermal insulation device sequentially from bottom to top, and each of the first thermal insulation device and the second thermal insulation device is removably arranged; the periphery of the condensing zone is further provided with a liquid cooling device; a gas inlet and a gas outlet are formed in the condensing zone; and an inner wall of the condensing zone is provided with an arrangement structure configured to arrange a collection device. A heating temperature of a material and condensation conditions in the condensing zone are controlled to make an evaporated magnesium vapor condensed on the collection device in the condensing zone.Type: ApplicationFiled: January 11, 2024Publication date: May 2, 2024Applicant: KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Yang TIAN, Dong LIANG, Bin YANG, Baoqiang XU, Dachun LIU, Fei WANG, Yifu LI, Wenlong JIANG, Yong DENG, Jian WU, Lipeng WANG
-
Patent number: 11957717Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.Type: GrantFiled: April 9, 2021Date of Patent: April 16, 2024Assignee: HRAIN BIOTECHNOLOGY CO., LTD.Inventors: Fei Huang, Tao Peng, Xuemei Zou, Pinglei Liu, Dachun Liu, Hui Huang
-
Publication number: 20230312601Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 30, 2023Publication date: October 5, 2023Inventors: Daniel Cohen, Jane Gong, Tarun Jain, Puneet Kumar, Dachun Liu, Anthony Mastracchio, Mark Mills, Andrew William Phillips, John K. Pratt, Sreenivas Punna, Jennifer Ann Stockwell, Le Wang, Yiyun Yu
-
Publication number: 20230285378Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: September 9, 2022Publication date: September 14, 2023Applicant: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Warren M. Kati, Tammie K. Jinkerson, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Publication number: 20230241104Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.Type: ApplicationFiled: April 9, 2021Publication date: August 3, 2023Inventors: Fei HUANG, Tao PENG, Xuemei ZOU, Pinglei LIU, Dachun LIU, Hui HUANG
-
Publication number: 20230158039Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: June 30, 2022Publication date: May 25, 2023Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
-
Publication number: 20220017511Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: February 24, 2021Publication date: January 20, 2022Applicant: AbbVie Inc.Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
-
Publication number: 20210236508Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: August 18, 2020Publication date: August 5, 2021Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
-
Publication number: 20210130346Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.Type: ApplicationFiled: April 14, 2017Publication date: May 6, 2021Applicant: AbbVie Inc.Inventors: David Hardee, Jason Brewer, Lisa Hasvold, Dachun Liu, Keith McDaniel, Michael Schrimpf, George Sheppard
-
Patent number: 10982299Abstract: A method for comprehensively processing noble lead provided and utilizes two instances of vacuum distillation to realize an open circuit of arsenic, lead, antimony and bismuth and the high-efficiency enrichment of precious metals of gold and silver, and can obtain elemental arsenic, a lead-bismuth-antimony alloy, a silver alloy and a copper alloy, respectively. The lead-bismuth-antimony alloy, the silver alloy and the copper alloy are processed by oxidation refining, electrorefining and chlorination refining to obtain refined lead, refined antimony, antimony trioxide, electrolytic silver and electrolytic copper, and to realize gold enrichment. The entire process has advantages of high metal direct yield, low energy consumption, short flow chart, simple equipment, etc., and vacuum distillation belongs to a physical process in which the alloy can be separated only by means of the difference in saturated vapor pressure between the metals, without generation of wastewater, waste gas and waste residue.Type: GrantFiled: March 19, 2019Date of Patent: April 20, 2021Assignees: Kunming University of Science and Technology, Kunming Dingbang Technology Co., Ltd.Inventors: Bin Yang, Dachun Liu, Wenlong Jiang, Guozheng Zha, Baoqiang Xu, Weiping Dai, Yifu Li, Qingchun Yu, Xiumin Chen, Hongwei Yang, Yang Tian, Yong Deng, Fei Wang, Heng Xiong, Jia Yang, Tao Qu, Lingxin Kong
-
Publication number: 20210070756Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: November 16, 2020Publication date: March 11, 2021Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
-
Publication number: 20210047304Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: May 26, 2020Publication date: February 18, 2021Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
-
Publication number: 20200291027Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: March 23, 2020Publication date: September 17, 2020Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
-
Publication number: 20200255426Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: April 27, 2020Publication date: August 13, 2020Applicant: AbbVie Inc.Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
-
Publication number: 20200208238Abstract: A method for comprehensively processing noble lead provided and utilizes two instances of vacuum distillation to realize an open circuit of arsenic, lead, antimony and bismuth and the high-efficiency enrichment of precious metals of gold and silver, and can obtain elemental arsenic, a lead-bismuth-antimony alloy, a silver alloy and a copper alloy, respectively. The lead-bismuth-antimony alloy, the silver alloy and the copper alloy are processed by oxidation refining, electrorefining and chlorination refining to obtain refined lead, refined antimony, antimony trioxide, electrolytic silver and electrolytic copper, and to realize gold enrichment. The entire process has advantages of high metal direct yield, low energy consumption, short flow chart, simple equipment, etc., and vacuum distillation belongs to a physical process in which the alloy can be separated only by means of the difference in saturated vapor pressure between the metals, without generation of wastewater, waste gas and waste residue.Type: ApplicationFiled: March 19, 2019Publication date: July 2, 2020Inventors: Bin Yang, Dachun Liu, Wenlong Jiang, Guozheng Zha, Baoqiang Xu, Weiping Dai, Yifu Li, Qingchun Yu, Xiumin Chen, Hongwei Yang, Yang Tian, Yong Deng, Fei Wang, Heng Xiong, Jia Yang, Tao Qu, Lingxin Kong
-
Patent number: 10633379Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: GrantFiled: April 14, 2017Date of Patent: April 28, 2020Assignee: AbbVie Inc.Inventors: Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, George Sheppard, Le Wang
-
Publication number: 20190389861Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: January 22, 2019Publication date: December 26, 2019Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
-
Publication number: 20190382383Abstract: Provided herein are compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: October 14, 2016Publication date: December 19, 2019Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
-
Publication number: 20190345153Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: April 14, 2017Publication date: November 14, 2019Applicant: AbbVie Inc.Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
-
Publication number: 20190284658Abstract: A device is provided for fractional condensation of an arsenic-lead vapor mixture and an application method thereof. The device includes a vacuumizing device, a flange, temperature measuring devices, a graded vacuum furnace body, a quartz tube, a push rod, a control cabinet, a heating zone and recycled foil. The length of the quartz tube is 1.2-2 m; the length of the heating zone is 0.15-0.25 m; and the quartz tube is provided with one temperature measuring device every 2-3 cm. The device forms a certain temperature gradient in the quartz tube, so that a material condenses in the corresponding temperature range, thereby achieving the purpose of high-efficiency separation.Type: ApplicationFiled: March 13, 2019Publication date: September 19, 2019Inventors: Yifu Li, Zhenghao Pu, Bin Yang, Baoqiang Xu, Dachun Liu, Yang Tian, Wenlong Jiang, Neng Xiong, Huan Zhang